Search

Your search keyword '"Briere J."' showing total 498 results
Start Over Author "Briere J."
498 results on '"Briere J."'

1. BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial

Author

Petrella, T., Copie-Bergman, C., Brière, J., Delarue, R., Jardin, F., Ruminy, P., Thieblemont, C., Figeac, M., Canioni, D., Feugier, P., Fabiani, B., Leroy, K., Parrens, M., André, M., Haioun, C., Salles, G.A., Gaulard, P., Tilly, H., Jais, J.P., and Molina, T.J.

Published
2017
Full Text
View/download PDF

4. 623MO Machine learning-based prediction of germinal center, MYC/BCL2 double protein expressor status, and MYC rearrangement from whole slide images in DLBCL patients

Author

Syrykh, C., primary, Schiratti, J-B., additional, Brion, E., additional, Joubert, C., additional, Baia, M., additional, Marlot, L., additional, Maussion, C., additional, Danneaux, L.-W., additional, Bologna, S., additional, Briere, J., additional, Dartigues, P., additional, Gaulard, P., additional, Haioun, C., additional, Jardin, F., additional, Molina, T., additional, Tilly, H., additional, Gomez, E., additional, Sondaz, D., additional, Copie-Bergman, C., additional, and Laurent, C., additional

Published
2022
Full Text
View/download PDF

9. Epidemiology of patients with peripheral artery disease undergoing revascularization in England

Author

Portas, L, Bauersachs, R, Bowrin, K, Briere, J-B, Cohen, A, Huelsebeck, M, Schuyler, J, Quint, JK, and Bayer Ag

Subjects
body regions, Cardiovascular System & Hematology, food and beverages, 1103 Clinical Sciences
Abstract

Background: Symptoms, severity, and acuteness of peripheral artery disease (PAD) are major determinants of severe limb symptoms, subsequent risk of cardiovascular events and mortality. Lower extremity revascularization (LER) is a key option to relieve symptoms and to prevent limb loss in symptomatic PAD patients. This study aimed to quantify the burden of disease among patients with PAD-LER in England. Methods: Retrospective population-based study of linked primary and secondary care electronic health records, included 13,869 adult patients (aged ≥18 years) with PAD-LER from 2003 to 2018. The incidence of first ever PAD-LER was estimated overall and by type of procedure (endovascular/surgical). Health resource utilization associated with PAD-related complications and treatment patterns were assessed. Results: A high annual incidence of lower-limb revascularization (41.2 per 1,000 person years) and a nearly double incidence of endovascular first revascularization compared with open surgery were observed. More than 70% of patients with PAD-LER had a history of hyperlipidaemia and hypertension and roughly one-third were diabetic and had a history of coronary artery disease. Cardiovascular mortality accounting for one-third (34.1 per 1,000 person years) of all-cause mortality. Over 93% of patients were hospitalized for any reason and the commonest reasons for hospitalization were cardiovascular diseases and PAD with about one third hospitalized for revascularization re-occurrence. Conclusion: There is a significant burden of PAD-LER to the individual and society with ongoing healthcare resource utilization, treatment and increasing mortality.

Published
2022

10. Interferon Alpha and Cytosine Arabinoside in the Treatment of Chronic Myelogenous Leukemia

Author

Guilhot, F., Guerci, A., Michallet, M., Maloisel, F., Harousseau, J. L., Bouabdallah, R., Guyotat, D., Abgrall, J. F., Ifrah, N., Brière, J., Tertian, G., Bauters, F., Navarro, M., Morice, P., Christian, B., Vilque, J. M., Blanc, M., Hiddemann, W., editor, Büchner, T., editor, Wörmann, B., editor, Ritter, J., editor, Creutzig, U., editor, Keating, M., editor, and Plunkett, W., editor

Published
1998
Full Text
View/download PDF

11. Prospective Comparison of Allogeneic Bone Marrow Transplantation, Intensive Consolidation Chemotherapy, and Unpurged Autologous Bone Marrow Transplantation as Post-Remission Therapy in Adult Acute Myeloid Leukemia

Author

Harousseau, J. L., Pignon, B., Witz, F., Linassier, P., Lioure, B., Le Prise, P. Y., Cahn, J. Y., Desablens, B., Caillot, D., Ifrah, N., Abgrall, J. F., Guilhot, F., Guyotat, D., Mors, A., Casassus, P., Briere, J., Polin, V., Berthaud, P., Tellier, Z., Hurteloup, P., Büchner, T., editor, Schellong, G., editor, Ritter, J., editor, Creutzig, U., editor, Hiddemann, W., editor, and Wörmann, B., editor

Published
1997
Full Text
View/download PDF

13. Comparison of Chemotherapy and Autologous and Allogeneic Transplantation as Postinduction Regimen in Adult Acute Lymphoblastic Leukemia: a Preliminary Multicentric Study

Author

Fiere, D., Broustet, A., Leblond, V., Maraninchi, D., Castaigne, S., Flesch, M., Varet, B., Vernant, J. P., Milpied, N., Troussard, X., Pignon, B., Archimbaud, E., Dufour, P., Pris, J., Pico, J. L., Michallet, M., Gratecos, N., Briere, J., Travade, H., Guilhot, P., Desablens, B., Guy, H., Tilly, H., Jaubert, J., Witz, F., Büchner, T., editor, Schellong, G., editor, Hiddemann, W., editor, and Ritter, J., editor

Published
1990
Full Text
View/download PDF

18. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL

Author

Bologna, S, primary, Vander Borght, T, additional, Briere, J, additional, Ribrag, V, additional, Damaj, G. L, additional, Thieblemont, C, additional, Feugier, P, additional, Peyrade, F, additional, Lebras, L, additional, Coso, D, additional, Sibon, D, additional, Bonnet, C, additional, Morschhauser, F, additional, Ghesquieres, H, additional, Becker, S, additional, Olivier, P, additional, Fabiani, B, additional, Tilly, H, additional, Haioun, C, additional, and Bastie, J. N, additional

Published
2021
Full Text
View/download PDF

31. Prospective Comparison of Allogeneic Bone Marrow Transplantation, Intensive Consolidation Chemotherapy, and Unpurged Autologous Bone Marrow Transplantation as Post-Remission Therapy in Adult Acute Myeloid Leukemia

Author

Harousseau, J. L., primary, Pignon, B., additional, Witz, F., additional, Linassier, P., additional, Lioure, B., additional, Le Prise, P. Y., additional, Cahn, J. Y., additional, Desablens, B., additional, Caillot, D., additional, Ifrah, N., additional, Abgrall, J. F., additional, Guilhot, F., additional, Guyotat, D., additional, Mors, A., additional, Casassus, P., additional, Briere, J., additional, Polin, V., additional, Berthaud, P., additional, Tellier, Z., additional, and Hurteloup, P., additional

Published
1997
Full Text
View/download PDF

33. HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R-CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY

Author

Cottereau, A., primary, Vercellino, L., additional, Casasnovas, O., additional, Tilly, H., additional, Feugier, P., additional, Fruchart, C., additional, Roulin, L., additional, Oberic, L., additional, Pica, G., additional, Ribrag, V., additional, Abraham, J., additional, Simon, M., additional, Gonzalez, H., additional, Bouabdallah, R., additional, Fitoussi, O., additional, Sebban, C., additional, Lopez, A., additional, Macro, M., additional, Sahnes, L., additional, Morschhauser, F., additional, Trotman, J., additional, Corront, B., additional, Choufi, B., additional, Snauwaert, S., additional, Godmer, P., additional, Copie-Bergman, C., additional, Briere, J., additional, Salles, G., additional, Gaulard, P., additional, Meignan, M., additional, and Thieblemont, C., additional

Published
2019
Full Text
View/download PDF

37. Comparison of Chemotherapy and Autologous and Allogeneic Transplantation as Postinduction Regimen in Adult Acute Lymphoblastic Leukemia: a Preliminary Multicentric Study

Author

Fiere, D., primary, Broustet, A., additional, Leblond, V., additional, Maraninchi, D., additional, Castaigne, S., additional, Flesch, M., additional, Varet, B., additional, Vernant, J. P., additional, Milpied, N., additional, Troussard, X., additional, Pignon, B., additional, Archimbaud, E., additional, Dufour, P., additional, Pris, J., additional, Pico, J. L., additional, Michallet, M., additional, Gratecos, N., additional, Briere, J., additional, Travade, H., additional, Guilhot, P., additional, Desablens, B., additional, Guy, H., additional, Tilly, H., additional, Jaubert, J., additional, and Witz, F., additional

Published
1990
Full Text
View/download PDF

38. Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course

Author

Pignon, B., Witz, F., Desablens, B., Leprise, P. Y., Francois, S., Linassier, C., Berthou, C., Caillot, D., Lioure, B., Cahn, J. Y., Casassus, P., Sadoun, A., Audhuy, B., Guyotat, D., Briere, J., Vilque, J. P., Baranger, L., Polin, V., Berthaud, P., Hurteloup, P., Herve, P., and Harousseau, J. L.

Published
1996

40. Primary lymphoma of the central nervous system: an unresolved therapeutic problem

Author

Socie, G., Piprot-Chauffat, C., Schlienger, M., Legars, D., Thurel, C., Mikol, J., Ifran, N., Briere, J., Pene, F., Gindrey-Vie, B., Marin, J.L., Desablens, B., and Laugier, A.

Subjects
Non-Hodgkin's lymphomas -- Care and treatment, Nervous system tumors -- Care and treatment, Chemotherapy -- Evaluation, Health
Abstract

Lymphomas of the central nervous system are relatively rare; only about 1 percent of all brain tumors are lymphomas. Thirty-five cases of primary central nervous system lymphoma, all of which were of the non-Hodgkin's type, were reviewed. The median survival time was found to be three years, and the disease-free survival time was 16 months. Among the cases reviewed, there were no statistically significant differences between the patients receiving radiotherapy and those receiving both radiotherapy and chemotherapy. The relapse rate was 37.5 percent, and only one relapsing patient survived past eight months. Other reports have suggested that the long-term survival rate for non-Hodgkin's lymphoma of the central nervous system is roughly 10 percent. Although some researchers have suggested that chemotherapy plays an important role in the management of central nervous system lymphoma, this position is not supported by the cases reviewed here. Perhaps further research with more effective chemotherapeutic protocols may result in more promising survival rates. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

46. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis

Author

Michiels, J.J., Kutti, J., Stark, P., Bazzan, M., Gugliotta, L., Marchioli, R., Griesshammer, M., van Genderen, P.J.J., Brière, J., Kiladjian, J.J., Barbui, T., Finazzi, G., Berlin, N.I., Pearson, T.C., Green, A.C., Fruchtmann, S.M., Silver, R.T., Hansmann, E., Wehmeier, A., Lengfelder, E., Landolfi, R., Kvasnicka, H.M., Hasselbalch, H., Cervantes, F., Reilly, J.T., Demory, J.-L., Gisslinger, H., Guardiola, Ph., Martyré, M.C., Le Bousse-Kerdilès, M.C., and Thiele, J.

Published
1999
Full Text
View/download PDF

47. A Study of the Agreement of Medical Information Application to Histological Slide Readings in Chronic Lymphocytic Leukemia

Author

Ployart, F., Raphael, M., Auquier, A., Diebold, J., Brousse, N., Briere, J., Chomette, G., Caulet, T., Mayer, S., Imbert, M., Jouault, H., Delsol, G., Laumonier, R., Halkin, E., Antin, G., Sultan, Cl., Chastang, Cl., Binet, J. L., Gremy, F., Lindberg, D. A. B., editor, Reichertz, P. L., editor, O’Moore, R. R., editor, Barber, B., editor, and Roger, F., editor

Published
1982
Full Text
View/download PDF

48. Overall survival impact of BEACOPP versus ABVD in advanced hodgkin lymphoma: a pooled analysis of 4 randomized trials

Author

Andre, M., Fortpied, C., Viviani, S., Bellei, M., Carde, P., Hutchings, M., Gianni, A., Brice, P., Casasnovas, O., Gobbi, P., Zinzani, P. L., Dupuis, J., Iannitto, E., Rambaldi, A., Briere, J., Perrot, A., Heczko, M., Valagussa, P., Jonathan Douxfils, Joubert, C., Federico, M., Mounier, N., CHU UCL Namur, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione 'Istituto Neurologico Nazionale C. Mondino', Università degli Studi di Modena e Reggio Emilia (UNIMORE), Institut Gustave Roussy (IGR), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Fondazione IRCCS Istituto Nazionale dei Tumori, Service d'hématologie greffe [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Lipides - Nutrition - Cancer (U866) (LNC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Service d'Hématologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Research Unit in Environmental and Evolutionary Biology (URBE), Rue de Bruxelles 61, Facultés Universitaires Notre Dame de la Paix (FUNDP), Hôpital Archet 2 [Nice] (CHU), université de Bourgogne, LNC, European Organisation for Research and Treatment of Cancer [Bruxelles] ( EORTC ), European Cancer Organisation [Bruxelles] ( ECCO ), Istituto di Ricovero e Cura a Carattere Scientifico ( IRCCS ), Università di Modena e Reggio Emilia - UNIMORE (Modena, Italy), Institut Gustave Roussy ( IGR ), Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), service hématologie Besançon, CHU, Faculté Universitaire Notre Dame de la Paix ( FUNDP ), and Hôpital Archet 2 [Nice] ( CHU )

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Survival impact, [ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology, ABVD, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hodgkin lymphoma, BEACOPP, Chimiothérapie
Abstract

IF 6.671; International audience

Published
2016

49. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

Author

Dubois , Sydney, Viailly , J., Mareschal , Sylvain, Bohers , Elodie, Bertrand , P., Ruminy , Philippe, Maingonnat , Catherine, Jais , Jean-Philippe, Peyrouze , Pauline, Figeac , Martin, Molina , Thierry, Desmots , Fabienne, Fest , Thierry, Haioun , Corinne, Lamy , Thierry, Copie-Bergman , Christiane, Briere , J., Petrella , Tony, Canioni , Danielle, Fabiani , Bettina, Coiffier , Bertrand, Delarue , Richard, Peyrade , Frédéric, Bosly , A., Andre , M., Ketterer , Nicolas, Salles , Gilles, Tilly , Hervé, Leroy , Karen, Jardin , Fabrice, Viailly , Pierre-Julien, Bertrand , Bertrand, Brière , Josette, André , André, André , Marc, Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Service d'informatique médicale et biostatistiques [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de recherche des Cordeliers - Equipe 20 'ingénierie des connaissances en santé', Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Faculté de Médecine Henri Warembourg - Université de Lille, Plateforme de génomique fonctionnelle et structurelle [Lille], Institut pour la recherche sur le cancer de Lille [Lille] (IRCL)-Université de Lille, Droit et Santé, Service d'anatomie pathologique [CHU Necker], Microenvironnement et cancer (MiCa), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), INSERM U955, équipe 9, Département de pathologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Gvh et Gvl : Physiopathologie Chez l'Homme et Chez l'Animal, Incidence et Role Therapeutique, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'anatomo-pathologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Hôpital Maisonneuve-Rosemont, Centre de référence des mastocytoses (CEREMAST), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'anatomie et cytologie pathologiques [CHU Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d'Hematologie, Hospices Civils de Lyon (HCL)-Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Laboratoire de Biologie Moléculaire de la Cellule (LBMC), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'immuno-hématologie pédiatrique [CHU Necker], Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), CHU Dinant-Godinne UCL Namur, Department of Oncology, Lausanne Hospital, Lausanne Hospital, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Service de Pathologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut National du Cancer (INCA), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Jonchère, Laurent, Rouen Business School, Groupe d'étude des proliférations lymphoïdes ( GPL ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de Recherche des Cordeliers ( CRC ), Université Paris Diderot - Paris 7 ( UPD7 ) -École pratique des hautes études ( EPHE ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Lille 2 - Faculté de Médecine, Institut pour la recherche sur le cancer de Lille [Lille] ( IRCL ) -Université de Lille, Droit et Santé, AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Microenvironment, Cell Differentiation, Immunology and Cancer ( MICMAC ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Groupe Henri Mondor-Albert Chenevier, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Hôpital Albert Chenevier, Maisonneuve-Rosemont Hospital Research Center, University of Montreal, Service de pathologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Centre Antoine Lacassagne, CRLCC Antoine Lacassagne, Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes ( LITIS ), Université Le Havre Normandie ( ULH ), Normandie Université ( NU ) -Normandie Université ( NU ) -Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Institut national des sciences appliquées Rouen Normandie ( INSA Rouen Normandie ), Normandie Université ( NU ), Unité de Taphonomie médico-légale ( UTML ), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Centre de Recherche des Cordeliers ( CRC (UMR_S 872) ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Microenvironnement et cancer ( MiCa ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ) -Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre de référence des mastocytoses, Service d'anatomie et cytologie pathologiques, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Hospices Civils de Lyon ( HCL ) -Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ), Laboratoire de Biologie Moléculaire de la Cellule ( LBMC ), École normale supérieure - Lyon ( ENS Lyon ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Côte d'Azur (UCA)-UNICANCER, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (MGD) Service d'hématologie, Groupe d'étude des proliférations lymphoïdes, Université de Rouen - Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC) - École pratique des hautes études (EPHE) - Université Paris Diderot - Paris 7 (UPD7) - Université Paris Descartes - Paris 5 (UPD5) - Institut National de la Santé et de la Recherche Médicale (INSERM), Institut pour la recherche sur le cancer de Lille [Lille] (IRCL) - Université de Lille, Droit et Santé, Université de Rennes 1 (UR1) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Henri Mondor - Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Henri Mondor - Hôpital Albert Chenevier, Assistance publique - Hôpitaux de Paris (AP-HP) - Groupe Hospitalier Saint-Louis-Lariboisière- Fernand-Widal - Université Paris Diderot - Paris 7 (UPD7), Centre de pathologie, Assistance publique - Hôpitaux de Paris (AP-HP) - AP-HP Hôpital Necker - Enfants Malades [Paris], Université Pierre et Marie Curie - Paris 6 (UPMC) - Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Saint-Antoine [APHP], Service de Radio-Oncologie [Lyon], Hospices Civils de Lyon - Centre Hospitalier Lyon Sud [Pierre Bénite], Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) - Université Paris Descartes - Paris 5 (UPD5) - AP-HP Hôpital Necker - Enfants Malades [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM) - IFR10 - Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Le Havre Normandie (ULH) - Université de Rouen - Institut National des Sciences Appliquées - Rouen (INSA Rouen), and Institut National des Sciences Appliquées (INSA) - Institut National des Sciences Appliquées (INSA)

Subjects
0301 basic medicine, [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Cancer Research, Receptors, Cytoplasmic and Nuclear, Cell Cycle Proteins, TUMOR-SUPPRESSOR GENE, Genome, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Antibodies, Monoclonal, Murine-Derived, 0302 clinical medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, PROGNOSTIC-SIGNIFICANCE, [ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, Molecular Targeted Therapy, Prospective Studies, Precision Medicine, Exome sequencing, Genetics, Oncogene Proteins, B-Lymphocytes, High-Throughput Nucleotide Sequencing, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, 3. Good health, DNA-Binding Proteins, GENOME, Phosphotransferases (Alcohol Group Acceptor), Oncology, Vincristine, 030220 oncology & carcinogenesis, [SDV.IMM]Life Sciences [q-bio]/Immunology, Rituximab, Lymphoma, Large B-Cell, Diffuse, medicine.drug, EXPRESSION, [SDV.IMM] Life Sciences [q-bio]/Immunology, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, FREQUENT, Biology, Karyopherins, DNA sequencing, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, TARGETS, Exome Sequencing, medicine, Humans, RITUXIMAB, Cyclophosphamide, Tumor Necrosis Factor alpha-Induced Protein 3, Gene Expression Profiling, CLASSICAL HODGKIN LYMPHOMA, SOMATIC MUTATIONS, Precision medicine, medicine.disease, Lymphoma, Gene expression profiling, 030104 developmental biology, Doxorubicin, GTP-Binding Protein alpha Subunits, Gq-G11, Prednisone, BURKITT-LYMPHOMA, Diffuse large B-cell lymphoma
Abstract

Purpose: Next-generation sequencing (NGS) has detailed the genomic characterization of diffuse large B-cell lymphoma (DLBCL) by identifying recurrent somatic mutations. We set out to design a clinically feasible NGS panel focusing on genes whose mutations hold potential therapeutic impact. Furthermore, for the first time, we evaluated the prognostic value of these mutations in prospective clinical trials. Experimental Design: A Lymphopanel was designed to identify mutations in 34 genes, selected according to literature and a whole exome sequencing study of relapsed/refractory DLBCL patients. The tumor DNA of 215 patients with CD20+de novo DLBCL in the prospective, multicenter, and randomized LNH-03B LYSA clinical trials was sequenced to deep, uniform coverage with the Lymphopanel. Cell-of-origin molecular classification was obtained through gene expression profiling with HGU133+2.0 Affymetrix GeneChip arrays. Results: The Lymphopanel was informative for 96% of patients. A clear depiction of DLBCL subtype molecular heterogeneity was uncovered with the Lymphopanel, confirming that activated B-cell–like (ABC), germinal center B-cell like (GCB), and primary mediastinal B-cell lymphoma (PMBL) are frequently affected by mutations in NF-κB, epigenetic, and JAK–STAT pathways, respectively. Novel truncating immunity pathway, ITPKB, MFHAS1, and XPO1 mutations were identified as highly enriched in PMBL. Notably, TNFAIP3 and GNA13 mutations in ABC patients treated with R-CHOP were associated with significantly less favorable prognoses. Conclusions: This study demonstrates the contribution of NGS with a consensus gene panel to personalized therapy in DLBCL, highlighting the molecular heterogeneity of subtypes and identifying somatic mutations with therapeutic and prognostic impact. Clin Cancer Res; 22(12); 2919–28. ©2016 AACR. See related commentary by Lim and Elenitoba-Johnson, p. 2829

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results